Romidepsin and Afatinib Abrogate Jak-Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma

Shih, B. B., Ma, C., Cortes, J. R., Reglero, C., Miller, H., Quinn, S. A., Albero, R., Laurent, A. P., Mackey, A., Ferrando, A. A., Geskin, L., & Palomero, T. (2024). Romidepsin and Afatinib Abrogate Jak–Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 144(7), 1579-1589.e8. https://doi.org/10.1016/j.jid.2023.12.010
Authors:
Bobby B Shih
Cindy Ma
Jose R Cortes
Clara Reglero
Hannah Miller
S Aidan Quinn
Robert Albero
Anouchka P Laurent
Adam Mackey
Adolfo A Ferrando
Larisa Geskin
Teresa Palomero
Affiliated Authors:
Bobby B Shih
Cindy Ma
Jose R Cortes
Clara Reglero
Hannah Miller
S Aidan Quinn
Robert Albero
Anouchka P Laurent
Adam Mackey
Adolfo A Ferrando
Larisa Geskin
Teresa Palomero
Columbia Affiliation:
Subjects:
Classification and Treatment of Cutaneous Lymphomas (OpenAlex Topic)
Human T-cell Leukemia Virus Type 1 Infection (OpenAlex Topic)
Lymphoid Neoplasms (OpenAlex Topic)
Depsipeptides (MeSH)
Lymphoma, T-Cell, Cutaneous (MeSH)
Afatinib (MeSH)
Signal Transduction (MeSH)
Drug Synergism (MeSH)
Skin Neoplasms (MeSH)
Author Keywords:
combination therapy
cutaneous t-cell lymphoma
preclinical models
romidepsin
cutaneous t -cell lymphoma
elink
Publication Type:
Article
Unique ID:
10.1016/j.jid.2023.12.010
PMID:
38219917
DOI:
10.1016/j.jid.2023.12.010
Journal:
Journal of Investigative Dermatology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View OpenAlex Record
View Scopus Record
View Web of Science Record

Record Created: